Publication:
Effectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study.

Simple item page
dc.contributor.authorSuárez-García, Inés
dc.contributor.authorMoreno, Cristina
dc.contributor.authorRuiz-Algueró, Marta
dc.contributor.authorPérez-Elías, María Jesús
dc.contributor.authorNavarro, Marta
dc.contributor.authorDíez Martínez, Marcos
dc.contributor.authorViciana, Pompeyo
dc.contributor.authorPérez-Martínez, Laura
dc.contributor.authorGórgolas, Miguel
dc.contributor.authorAmador, Concha
dc.contributor.authorde Zárraga, Miguel Alberto
dc.contributor.authorJarrín, Inma
dc.contributor.authorCohort of the Spanish HIV/AIDS Research Network (CoRIS)
dc.date.accessioned2023-02-09T09:37:07Z
dc.date.available2023-02-09T09:37:07Z
dc.date.issued2020-07-20
dc.description.abstractThe aim of this study was to investigate the effectiveness and tolerability of the combination elvitegravir/cobicistat/tenofovir/emtricitabine plus darunavir (EVG/COB/TFV/FTC + DRV) in treatment-experienced patients from the cohort of the Spanish HIV/AIDS Research Network (CoRIS). Treatment-experienced patients starting treatment with EVG/COB/TFV/FTC + DRV during the years 2014-2018 and with more than 24 weeks of follow-up were included. TFV could be administered either as tenofovir disoproxil fumarate or tenofovir alafenamide. We evaluated virological response, defined as viral load (VL)  We included 39 patients (12.8% women). At baseline, 10 (25.6%) patients had VL  EVG/COB/TFV/FTC + DRV was well tolerated and effective in treatment-experienced patients with undetectable viral load as a simplification strategy, allowing once-daily, two-pill regimen with three antiretroviral drug classes. Effectiveness was low in patients with detectable viral loads.
dc.identifier.doi10.1186/s12981-020-00302-2
dc.identifier.essn1742-6405
dc.identifier.pmcPMC7372769
dc.identifier.pmid32690099
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7372769/pdf
dc.identifier.unpaywallURLhttps://doi.org/10.1186/s12981-020-00302-2
dc.identifier.urihttp://hdl.handle.net/10668/15964
dc.issue.number1
dc.journal.titleAIDS research and therapy
dc.journal.titleabbreviationAIDS Res Ther
dc.language.isoen
dc.organizationHospital Universitario Virgen del Rocío
dc.page.number45
dc.pubmedtypeJournal Article
dc.pubmedtypeMulticenter Study
dc.pubmedtypeResearch Support, Non-U.S. Gov't
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectCohort studies
dc.subjectDarunavir
dc.subjectHIV infection
dc.subjectHighly active antiretroviral therapy
dc.subject.meshAdult
dc.subject.meshAnti-HIV Agents
dc.subject.meshCobicistat
dc.subject.meshDarunavir
dc.subject.meshDrug Therapy, Combination
dc.subject.meshEmtricitabine
dc.subject.meshFemale
dc.subject.meshHIV Infections
dc.subject.meshHIV-1
dc.subject.meshHumans
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshQuinolones
dc.subject.meshSpain
dc.subject.meshTenofovir
dc.subject.meshTreatment Outcome
dc.subject.meshViral Load
dc.titleEffectiveness of the combination elvitegravir/cobicistat/tenofovir/emtricitabine (EVG/COB/TFV/FTC) plus darunavir among treatment-experienced patients in clinical practice: a multicentre cohort study.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number17
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
PMC7372769.pdf
Size:
784.13 KB
Format:
Adobe Portable Document Format
Download

Collections

SAS - Hospital Universitario Virgen del Rocío

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía